title: Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial.
abstract: BACKGROUND
  Miconazole is an antimycotic agent with bacteriocidal activity against Helicobacter pylori in vitro. Its role in the clinical eradication of H. pylori has not been studied. The objective of this study was to investigate the efficacy and side effect profile of miconazole for the treatment of H. pylori.
  
  
  METHODS
  We studied 65 patients with gastritis or peptic ulcer disease in whom H. pylori infection was confirmed by a rapid urease test and microbiologic assessment. In vitro miconazole sensitivity was assessed for the H. pylori strains isolated from the enrolled patients. All patients were randomized to receive either dual therapy consisting of lansoprazole 30 mg daily and amoxicillin 500 mg three times a day for 14 days (LA, n = 33) or triple therapy using the LA regimen plus miconazole gel 100 mg three times a day for 14 days (LAM, n = 32). At least 8 weeks after the treatment, successful therapy was validated by the histological and microbiologic assessment. Adverse effects and drug adherence were monitored by direct questioning.
  
  
  RESULTS
  The minimum inhibitory concentrations of miconazole ranged from 3.13 to 6.25 mg/L. H. pylori was eradicated in 16 of 33 patients (48%, 95% CI = 31% to 67%) after LA therapy, and 24 of 32 patients (75%, 95% CI = 59% to 91%) after LAM therapy (p < .03). There was no significant difference in the occurrence of adverse events between the two groups.
  
  
  CONCLUSIONS
  The addition of miconazole gel to the LA regimen significantly improved the cure rate of H. pylori without an increase in adverse effects.
authors.affiliation: Department of Internal Medicine, Mito Kyodo General Hospital, Ibaraki, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ikezawa
authors.forename: H
authors.initials: H
authors.lastname: Kashimura
authors.forename: H
authors.initials: H
authors.lastname: Mahmudul
authors.forename: A
authors.initials: A
authors.lastname: Nakahara
authors.forename: A
authors.initials: A
authors.lastname: Yanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuzaki
authors.forename: H
authors.initials: H
authors.lastname: Mutoh
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008825:Miconazole / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D005782:Gels; D010406:Penicillins; D064747:Lansoprazole; D008825:Miconazole; D000658:Amoxicillin; D009853:Omeprazole